Click here to see a list of our past events.
Female founders are bringing innovation, technology, medicine, wellness, and their own lived experiences together to advance women’s healthcare. Our Cornellian entrepreneurs will share their journeys starting women’s healthcare businesses, and how, through their companies and technologies, they’re addressing women’s unique needs and solving our most pressing health challenges. Join us to wrap up Women’s History Month with a look into the future!
Featuring:
- Andrea Ippolito ’06, MENG ’07, CEO & Founder, SimpliFed
- Eve McDavid, Cornell Tech Runway Post-doc Fall ’22 Cohort & CEO, Mission-Driven Tech
- J’Vanay Santos-Fabian MBA ’22, CEO & Co-Founder, MyLÚA Health
- Carolyn Witte ’12, CEO & Co-Founder, Tia
Calling all researchers! If you have been working on a technology innovation and wish to explore its commercialization potential, I-Corps can provide you with entrepreneurial education, mentoring, and up to $50,000 in funding for customer discovery.
Hosted by the Interior Northeast I-Corps Hub (IN I-Corps), the virtual NSF I-Corps Information Session on Tuesday, March 26 (12:00 – 12:45 p.m. ET) is designed for busy graduate students, postdocs, and faculty interested in learning more about I-Corps regional and national programming. I-Corps alumni Ruben Trujillo, a Ph.D. candidate at Cornell University, and Nancy Guo, a professor at West Virginia University and recent NSF SBIR awardee, will be in attendance to share their experiences and answer questions.
The National Science Foundation created I-Corps (Innovation Corps) to bridge the gap between fundamental research discoveries in science and engineering and the commercialization of technologies, products, and processes with the potential to benefit society.
Register: https://bit.ly/ICorpsMarch24
Do you have ideas for a new medical device, but aren't sure where to begin with initial design? Interested in learning how to utilize 3D printing to create prototypes and get your idea started? Back by popular demand, the BioVenture eLab, a part of Weill Cornell Medicine Enterprise Innovation, is offering a second basic seminar in 3D printing.
Join us at the BioVenture eLab makerspace to learn how to use specialized software and Google Sketch to create designs for 3D printing.
The seminar will feature our guest lecturer, NatalieDeana Badillo, a third-year medical student at Weill Cornell Medicine who possesses a biomedical engineering background. Natalie is also a member of the Biomedical Engineering Society and is President of the Arts & Crafts & 3D Printing Club at Weill Cornell Medicine. Register now.
Critical Path Institute’s (C-Path) Translational Therapeutics Accelerator (TRxA) is proud to announce its 2024 global Request for Proposals for its Breakthrough Research and Innovation in Drug Development Grants (BRIDGe).
BRIDGe awards are designed to support academic researchers by providing funding and defining optimal strategies for advancing new, cutting-edge therapeutics from the lab to patients. Projects eligible for BRIDGe awards include early lead optimization and IND-enabling studies, using small molecule approaches, anywhere in the world. Biologicals, including peptides or antibodies, oligonucleotides, cell and gene therapy applications and medical devices are not eligible at this time. Drug repurposing approaches are also not eligible during this funding cycle.
Please see attached documents for the 
details of the funding opportunity and also a pre-proposal template. To apply, send Deanna Scarcella (des4016@med.cornell.edu) a NON-CONFIDENTIAL (make sure to EXCLUDE any unpublished data or information) pre-proposal by Friday, March 22, 2024, which will be reviewed by the CTL. CTL will coordinate submitting the pre-proposal by the deadline of Fri, Mar 29. Contact Deanna if you have any questions.
Johnson & Johnson Innovation's annual JLABS Investor & Partnering Day will take place in New York City on Thursday, May 2, 2024, 8:30 am to 6 pm, and applications are now open for qualified, promising, early-stage biotech startups seeking pre-seed, seed, or series A funding in the next 12 to 18 months.
The day will consist of one-on-one matched meetings with strategically aligned life science investors, perspectives from experts including Johnson & Johnson Innovation – JJDC, Inc., a networking lunch, and a reception to provide additional opportunities to meet with investors and fellow biotech CEOs.
Please submit your application by March 22 and reach out to Miriam Huber if you have any questions. Note that there are limited spots available, so attendance is not guaranteed and is based on additional screening.
Applications Now Open for the BenDaniel Venture Challenge
The BenDaniel Venture Challenge (BVC) is Big Red Venture’s Annual Pitch Competition. BRV will select five finalists to pitch their business ideas to a panel of investors during Entrepreneurship at Cornell Celebration on April 12. Winners will earn a cash prize totaling $25,000 with an additional $25,000 match if the company’s technology is licensed through Cornell.
Companies based in New York state or with a Cornell affiliation are eligible to apply. Applications are open through March 22, 2024. Apply now.
Join scientists from the Sanders Tri-Institutional Therapeutics Discovery Institute as they share their broad knowledge of small molecule and biologics drug discovery. This mini-course will be provided in four sessions over the course of three weeks (4/1, 4/2, 4/8 and 4/15). Classes will be structured informally with ample opportunity for questions and discussion.
The course covers:
- An overview of Sanders TDI
- Target identification and validation
- Assays for drug discovery
- Assay development
- Screening methodologies
- Introduction to medicinal chemistry
- Introduction to computational chemistry and molecular modeling
- Antibody generation strategies
- Immunization strategies
- Antibody engineering and optimization
- Developability assessment
The number of seats is limited. Register now. Questions? Contact Leigh Baxt at lbaxt@tritdi.org.
The Mark Foundation Emerging Leader Awards support innovative cancer research from the next generation of leaders. These grants are awarded to outstanding early career investigators to support high-impact, high-risk projects that are distinct from their current research portfolio.
Award Terms
- The grant amount is $250,000 per year for three (3) years totaling $750,000.
- Indirect costs are not to exceed 10% of direct costs and are included in total.
- Emerging Leader Awards are granted to a single investigator; co-investigators are not permitted. The award may be used to support projects carried out with collaborators, who may provide letters of support.
- In Year 3, at The Mark Foundation’s discretion, select Awardees may be invited to apply for up to two (2) years of additional funding depending on project progress.
- The letter of agreement will include IP terms with a revenue sharing component.
- Award start date will be January 1, 2025.
The portal to submit letters of intent for the upcoming Emerging Leader Award will open on March 20, 2024. Letters of Intent must be submitted through the online application system no later than 5 PM Eastern Time on Monday, April 29, 2024. Learn more about the application process here.
Center for Technology Licensing (CTL) at Weill Cornell Medicine is offering a special opportunity to meet personally with Jason Novak, J.D., of Norton Rose Fulbright, whose specialties in health care and AI will provide valuable information to the Weill Cornell Medicine community following his March 18 panel appearance on the topics at Cornell Tech.
Jason has extensive experience in IP and data rights strategy. For data rights, Jason advises clients on transactions, protection and general strategy. On the IP front, Jason's experience extends to patent portfolio management, preparation and prosecution, oppositions, counseling, licensing and technology transactions, in and out-licensing, freedom-to-operate, various types of due diligence, IP training, risk recognition and management and dispute resolution.
Register for your 1:1 session now!
This panel discussion delves into data rights in AI-related technologies and strategies for successful commercialization. Panelists include Jason Novak of Norton Rose Fulbright, Fernando Gómez-Baquero, Director of the Runway Startup Postdoc and Spinout Programs, and Vince Hartman, Co-founder and CEO of Abstractive Health. This engaging session will offer a multifaceted view on leveraging AI technologies for commercial success, ensuring data rights, and navigating the evolving landscape of AI commercialization. Food and drink networking reception to follow!
Register here.
